Instrument Inactif

Communiqués Santhera Pharmaceuticals Holding AG Xetra

Actions

S3F

CH0027148649

Produits pharmaceutiques

Communiqués

13/07	Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus	AQ
01/07	Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®	AQ
02/06	Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea	AQ
26/05	Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting	AQ
05/05	Santhera Publishes Agenda for its Annual General Meeting	AQ
30/04	Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors	AQ
28/04	Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy	AQ
28/04	Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025	AQ
27/04	Santhera Pharmaceuticals : Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU	PU
12/03	Santhera Pharmaceuticals : Full Year 2025 Trading Update	PU
10/03	Santhera Pharmaceuticals : Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth	PU
09/03	AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy	AQ
09/03	Santhera Pharmaceuticals : AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy	PU
27/02	Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy	AQ
10/02	Santhera Pharmaceuticals : Appoints Stifel as Corporate Finance Advisor	PU
15/01	Santhera Pharmaceuticals : Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy	PU
08/01	Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties	AQ
05/11	Santhera Pharmaceuticals : Closes USD 13 Million Royalty Monetization Agreement	PU
04/11	Santhera Pharmaceuticals : Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids	PU
09/10/25	Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia	AQ
03/10/25	Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy	AQ
25/09/25	Santhera Pharmaceuticals : Provides Update on Convertible Bond Issued on 23 September 2025	PU
23/09/25	Santhera Pharmaceuticals : Announces Half Year 2025 Financial Results and Provides Corporate Update	PU
23/09/25	Santhera Pharmaceuticals : Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout	PU
23/09/25	Santhera Pharmaceuticals : 2025 Santhera Interim Report	PU